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Summanr Flunarizine. a diphenylpiperazine calcium channel blocker. is known to increase tumour blood
flow. It also interferes with calmodulin function. repair of DNA damage and drug resistance associated with
P-glvcoprotein. Flunarizine was tested for its ability to modulate either cyclophosphamide- or melphalan-
induced growth delay for a drug-resistant rhabdomyosarcoma xenograft (TE-671 MR) and the drug-sensitive
parent line (TE-671). in which P-glycoprotein is not involved in the mechanism of drug resistance. Tumour
blood flow was increased by 30% after a flunarizine dose of 4 mg kg-'. but no modification in growth delay
was induced by melphalan (12 mg kg-'). In contrast. a 60 mg kg- ' dose of flunarizine had no effect on tumour
blood flow. but the same dose created significant enhancement in melphalan-induced tumour regrowth delay in
both tumour lines. The dose-modifying factor for flunarizine as an adjuvant to melphalan was approximately 2
for both tumour lines. Although blood flow measurements were not performed with the combination of
flunarizine and melphalan, the results from flunarizine alone suggested that augmentation of melphalan
cytotoxicity is not mediated by changes in blood flow. In contrast. flunarizine did not affect drug sensitivity to
cyclophosphamide in groups of animals bearing the drug-sensitive parent tumour line. These results suggest
that the mechanism of drug sensitivity modification by flunarizine is not related to modification of tumour
blood flow, but may be mediated by modification of transport mechanisms that are differentially responsible
for cellular uptake and retention of melphalan as compared With cyclophosphamide.
Kevwords: calcium channel blocker: drug resistance; calmodulin; neoplasm transplantation; rhabdomyosar-
coma
Melphalan is a nitrogen mustard-based alkylating agent
active against a broad spectrum of malignancies. including
medulloblastoma and rhabdomyosarcoma (Horowitz et al.,
1988; Friedman et al.. 1989). Unfortunately, development of
melphalan resistance mediated by altered drug transport.
increased drug detoxification or increased repair of DNA
interstrand cross-links (Redwood and Colvin, 1980; Parsons
et al., 1981; Somfai-Relle et al., 1984; Gupta et al., 1989)
frequently prevents successful therapy of human neoplasia
with this agent, thus supporting development of therapeutic
approaches that are effective in bypassing or overcoming
drug resistance.
We have previously shown that melphalan resistance in a
human rhabdomyosarcoma line (TE-671 MR) is associated
with decreased drug accumulation relative to the drug-
sensitive parent line (Lilley et al.. 1991). Thus, methods that
increase drug uptake within tumour might increase the
therapeutic efficacy of melphalan in the resistant line. It has
been suggested that reversal of alkylator drug resistance by
calcium channel blockers may be due to an increase in drug
delivery as a consequence of improved blood flow (Stewart
and Evans, 1989).
Flunarizine. a diphenylpiperazine calcium channel blocker,
was selected as an agent to test whether increased tumour
blood flow would lead to increased drug efficacy in this
model system. There were several reasons for this choice.
First, studies show that flunarizine increased blood flow to
tumours (Kaelin et al.. 1984: Hill and Stirling, 1987; Vaupel
and Menke, 1989; Dewhirst et al.. 1992a). The effects are
more prominent in tumours that are hypoxic (Fenton and
Sutherland, 1992), and blood flow modification can be
achieved at dosages that do not alter cardiovascular function
(Kaelin et al.. 1984; Dewhirst et al., 1992a). Both the parent
and resistant sublines of TE-671 contain hypoxic regions in
vivo (Lilley et al., 1991). Thus. the agent would be expected
to be effective by increasing blood flow in both lines. A
second reason for choosing this agent is its reported activity
as an inhibitor of calmodulin. Calmodulin inhibitors have
been shown to restore drug sensitivity to tumour cells with
multiple drug resistance (MDR) mediated by increased P-
glycoprotein (Stewart and Evans. 1989). However. a few
reports have suggested that calmodulin inhibitors also reverse
resistance to drugs not characteristically associated with
MDR. such as cyclophosphamide (Hait et al.. 1989), cisplatin
(Kikuchi et al., 1986). nitrosoureas (Rose et al., 1978) and
bleomycin (Lazo et al., 1986).
Calmodulin inhibitors have also been reported to reduce
intracellular glutathione concentrations (Shenoy et al.. 1983).
and elevated glutathione content has proven responsible in
part for TE-671 MR resistance to melphalan (Rosenberg et
al., 1989). thus, flunarizine could alter drug resistance in this
model by reducing glutathione content.
We now report that flunarizine. administered at 4 mg kg-'
(i.p.). increases blood flow to TE-671 by 30%. but has no
effect on either TE-671 or TE-671 MR with regard to
melphalan-induced tumour regrowth delay. In contrast, a
flunarizine dosage of 60mgkg-' (i.p.) to both the resistant
and parent tumour lines significantly prolongs growth delay,
although it has no effect on tumour blood flow. This
enhancement of growth delay is accompanied by an increase
in tumour-plasma melphalan concentration ratios relative to
control tumours receiving melphalan alone.
Materials and methods
Animals and tumour models
All studies used male or female athymic BALB/c mice (nu nu
genotype, 6 weeks or older) maintained as previously de-
scribed (Redwood and Colvin, 1980; Bullard et al., 1981;
Parsons et al., 1981; Somfai-Relle et al., 1984; Gupta et al.,
1989). The human rhabdomyosarcoma xenograft TE-671
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(McAllister et al.. 1977: Stratton et al.. 1989) and the
melphalan-resistant subline TE-671 MR (Rosenberg et al..
1989) were used for all studies. Subcutaneous transplantation
of tumour homogenates (50pl) into the right flank of mice
were conducted as previously described (Friedman et al..
1986a).
Drugs
Melphalan was provided courtesy of Burroughs Wellcome
(Research Triangle Park. NC. USA) and administered as a
single i.p. dose in 17% dimethylsulphoxide. Cyclophos-
phamide was dissolved in saline at a concentration of
15.5mgml-' and was administered as a single dose (i.p.).
Flunarizine HCI was obtained from Sigma (St. Louis, MO,
USA) and solubilised in distilled water (pH 4.0) immediately
before use.
Phisiological studies
Non-tumour-bearing mice were anaesthetised with 2-5%
halothane-oxygen (0.5-2.0 1 min') and nitrous oxide (0.25 1
min-') by inhalation and restrained in a plaster of Paris cast
following a femoral artery cannulation. Once the cannulation
was completed, animals were allowed to recover, and the
catheter was connected to a pressure transducer (Microtip,
Millar Instruments. Houston, TX. USA). Output was
recorded on a strip chart recorder (Gould, Cleveland, OH.
USA) for later analysis. After the animals regained cons-
ciousness, the mean arterial pressure (MAP) was monitored
for 20 mmn before and 60 mmn after the administration of i.p.
flunarizine (4 mg kg-' and 60 mg kg-'). Body temperature
was monitored and maintained at 37-38°C throughout. In a
few animals, anaesthesia (ketamine 3 mg g-', xylazine 0.02
mg-g' body weight, i.m.) was used throughout the experi-
ment instead of allowing them to regain consciousness, as
referred to in the Results section.
Measurements of relative changes in tumour blood per-
fusion were made with laser Doppler velocimetry. Mice bear-
ing TE-671 xenografts were anaesthetised and restrained as
described above, while laser Doppler velocimetry probes were
placed into the tumour centre (0.8-mm-diameter probe)
through a preplaced catheter or over the surface of the
gastrocnemius muscle (0.8-mm-diameter probe). Once the
animals regained consciousness, the probes were alternately
connected to a single channel laser Doppler monitor (model
BPMH03A, TSI Instruments, St. Paul, MN, USA). The data
were reported as the average of 1 min recordings taken every
5 min for each monitored site. Results were reported and
analysed as relative change compared with baseline since the
device was not suited to absolute calibration in tumour tis-
sues (Acker et al.. 1990).
Therapy studies
Groups of 8-10 mice were randomised by tumour size and
treated when the median tumour volume exceeded 200 mm3
with melphalan. melphalan plus flunarizine, flunarizine alone
or drug vehicle. All animals receiving melphalan were treated
i.p. with 2.4. 12 or 18mgkg'; 24mgkg-' is 10% of the
lethal dose (LDIo). Flunarizine was administered at dosages
from 4 to 60mgkg-' (i.p.) 20min before and subsequently
at 8 and 16h after treatment with melphalan.
In a separate set of experiments. groups of 8-10 mice
bearing the drug-sensitive parent tumour line were ran-
domised by tumour size and treated, when the median
tumour volume exceeded 200 mm3. with i.p. cyclophos-
phamide. cyclophosphamide plus flunarizine or flunarizine
alone. Cyclophosphamide was given at doses of 115. 230 and
345mgkg-1; 460mgkg-' is 10% of the lethal dose.
Flunarizine was given at 60mgkg-' (i.p.).
Tumours were measured with vernier calipers (Scientific
Products. McGraw. IL. USA) everv 3-4 days. and volume
was calculated according to the following formula:
(width)' x (length)
I
Response of xenografts was assessed by growth delay. the
difference in days between the median time for the tumours
of treated (T) and control (C) animals to reach a volume of
five times greater than the volume at the time of original
treatment (T- C). Tumour regressions were defined as
tumours that decreased in size over two successive measure-
ments. relative to the volume at the day of treatment. We
report data in terms of tumour volumes because we have
previously shown in this laboratorx that strong correlations
exist between tumour volume measurements done with this
method and direct measures of tumour weight (Bullard et al.,
1981).
.4nalisis ofmelphalan uptak-e
Animals bearing TE-671 MR (six animals per group) were
treated with melphalan (24 mg kg-') via i.p. injection with or
without a prior dose of flunanrzine (60 mg kg- i.p.). Animals
were killed by cervical dislocation at 30. 60 and 120 min after
the melphalan injection. Blood was obtained immediately by
cardiac puncture. and the serum was separated by centrifuga-
tion and placed on dry ice. Subcutaneous xenografts were
simultaneously resected. weighed and frozen in liquid nit-
rogen. After thawing. they were homogenised with 10% per-
chloric acid (5:1, w v). Melphalan concentrations in plasma
and tumour samples were measured by high-pressure liquid
chromatography as previously described (Friedman et al.
1986b). Results were reported as mean tumour-plasma
ratios.
Statistical methods
The Wilcoxon rank order test was used to evaluate growth
delays and melphalan tumour-plasma ratios. The Fisher
exact test was used for tumour regression (Friedman et al..
1986a). Repeated measures analysis of variance was used to
test for relative changes between baseline (pretreatment) per-
fusion rate and time-monitored perfusion rates after
flunarizine administration (Snedecor and Cochran, 1967).
The null hypothesis was that drug administration caused no
relative change in perfusion. A two-tailed paired t-test was
used to compare MAPs before and after flunarizine adminis-
tration.
Results
Ph-isiological studies
MAP was measured in four anaesthetised animals (ketamine/
xylazine) and two conscious animals (as described in
Materials and methods) before and up to 60 min after
administration of flunarizine (4 mg kg-'). In the anaes-
thetised animals. MAP averaged 75.4 ± 6.6 mmHg (mean ±
s.d.) before drug administration and 75.4 ± 6.6 mmHg after.
In the conscious animals. mean baseline MAP was 102.5
mmHg and averaged 102.8 mmHg after drug administration.
Thus. a dose of 4 mg kg-' flunarizine created no detectable
change in MAP in either anaesthetised or conscious mice.
MAP was also measured in six conscious mice that received
60 mg kg- ' flunarizine. In this group, MAP averaged
91.5 ± 8.8 mmHg and 75.1 ± 9.1 mmHg before and after
flunarizine administration respectively. The observed change
in MAP was significant (P = 0.0337 two-tailed, paired t-test)
and represented an 18% drop relative to average predrug
MAP.
Relative changes in muscle and tumour blood flow were
measured in six and nine mice bearing TE-671 xenografts
receiving 4 and 60 mg kg-' flunarizine respectively (Figure 1).
A dose of 4 mg kg- increased tumour blood flow by 30% on
average, which was statistically significant (P<0.05). In con-Flunawne enhancemnt of mdpalpui actvty
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trast. no change in muscle blood flow was observed at that
dosage. Flunarizine did not affect either tumour or muscle
blood flow at a dose of 60 mg kg-
In vivo therapy studies
TE-671 Control tumours required 19-20 days to reach five
times initial tumour volume. Melphalan alone, at 2.4 mg
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Figre Relative change in (a) tumour blood flow and (b)
muscle blood flow, as monitored by laser Doppler fiowmetry. as
a function of time after flunarizine administration. Changes in
tumour blood flow after a 4 mg kg- dose were signiificant
(P<K0.05): changes in muscle blood flow were not statistically
significant. Error bars=s.e.m. 0. 4 mg kg ': 0. 60mgkg-'
kg- ', produced growth delays ranging from 20.2 to 25.2 days
in five separate experiments (Table I).
Flunarizine alone produced no significant growth delay in
three separate experiments. Combination therapy with mel-
phalan plus flunarizine at 4 mg kg-' and 8 mg kg-' doses
produced growth delays of 23.6 days and 26.7 days respec-
tively, the differences for which, when compared with mel-
phalan alone, were not statistically significant (P> 0.05). The
same combination therapy at 40 mg kg-' flunarizine pro-
duced a significant (P<0.01) increase in growth delay (27.0
days) over that achieved by melphalan alone (20.2 days); at
60 mg kg-' a growth delay of 33.7 days was produced, which
was also significantly (P<0.01) greater than that achieved by
melphalan alone (21.8 days). Treatment with melphalan plus
flunarizine induced tumour regressions, but these were not
statistically (P> 0.05) significant when compared with mel-
phalan alone.
Comparisons of growth delays at 2.4. 12 and 18 mg kg-'
revealed enhancement of regrowth delay at all doses when
flunarizine was added without an increase in mortality; no
animals died in either of the treatment groups. with observa-
tion times of over 30 days post treatment. The dose-modify-
ing factor was approximately 1.5-1.7 over this melphalan
dose range (Figure 2a).
No regressions were observed in any controls or animals
treated with flunarizine alone.
TE-671 MR Control tumours required 20-25 days to reach
five times initial tumour volume. Melphalan alone produced
growth delays ranging from 0.4 to 4.4 days in five separate
experiments (Table II). Flunarizine alone produced no
significant growth delay at 4 mg kg-' or 60 mg kg-'. Com-
bination therapy with melphalan plus flunarizine created
growth delays of 2.5 and 2.2 days with 4 mg kg-' flunarizine
and 2.2 and 2.8 days with 8 mg kg-' flunarizine with
differences that were not statistically significant (P> 0.10) as
compared with melphalan alone. Combination therapy with
melphalan plus flunarinzine at 60 mg kg-' induced an increase
in growth delay (10.3 days) that was statistically significant
(P<0.01) when compared with melphalan alone (4.1 days).
Tumour regressions with the same treatment were not statis-
tically (P>0.10) significant when compared with melphalan
alone.
Comparisons of growth delays at 2.4 and 12mgkg-'
revealed enhancement of growth delay without an increase in
mortality; no animals died in any of these treatment groups,
with observation times of over 30 days post treatment. The
dose-modifying factor was 2.3 over this melphalan dose
range (Figure 2b).
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Table I Treatment of athymic nude mice beanrng s.c. TE-671 xenografts with melphalan ± flunarizine
Experiment Treatmenta T- C (das)b` RegressionscA Isodose effect ratioe
I Melphalan 23.2 8/9 NA
Flunarizine (4 mg kg-1) -1.I (NS) 0/7 (NS)
Melphalan + flunarizine 23.6 919
2 Melphalan 21.9 818 NA
Melphalan + flunarizine (4 mg kg-') 24.8 9 9
3 Melphalan 25.2 9,10 NA
Flunarizine (8 mg kg-') -1.8 (NS) 011 O (NS)
Melphalan + flunarizine 26.7 10 10
4 Melphalan 20.2 5/7
Melphalan + flunarizine (40 mg kg-') 27.0f 9 9 1.3
5 Melphalan 21.8 9 10
Flunarizine (60 mg kg-') -2.04 (NS) 0/8 (NS)
Melphalan + flunarizine 33.7f 9/9 1.5
aMelphalan dose of36 mg m -2 (0.5 ofthe 10% lethal dose) in 17% dimethylsulphoxide viai.p. injection; flunarizine
at the indicated dosage in water (pH 4) via i.p. injection 20 min before and subsequently at 8 and 16 h after treatment
with melphalan or 17% dimethylsulphoxide (controls) via i.p. injection. bDifference in days between the median time
forthetumoursoftreated(T)andcontrol(C)animals toreach avolumeoffivetimesgreaterthanthevolumeat the time
of original treatment. cValues statistically significant (P<0.01) as compared with controls (treated with 17%
dimethylsulphoxide) except where indicated; NS. not significant. "Tumours that decreased in size over two successive
measurements total tumours. 'Ratio of growth delays of melphalan plus flunarizine/melphalan alone: NA. not
applicable. fStatistically significant (P<0.01) as compared with melphalan alone.kFlizine J of melphe adcity
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TE-671 studies with cyclophosphamide
Cyclophosphamide at 115, 230 and 345 mg kg-' yielded
growth delays of 9, 13.4 and 17.7 days respectively. When
flunarizine was added at a dose of 60 mg kg-', growth delays
were 11.7, 14.6 and 18.1 days respectively. All of these delays
were significant when compared with control animals
(P<0.001 in all cases), but there were no significant
differences between the groups with respect to presence or
absence of flunarizine.
No regressions were observed in any controls or
flunarizine-treated animals.
Effect offlunarizine on plasma and tumour melphalan levels
In mice bearing TE-671 MR, plasma levels of melphalan
appeared higher for the flunarizine group, but the differences
were not significant (P>0.25 for all time points) (Figure 3a).
In contrast, the mean tumour-plasma ratio of melphalan
was significantly higher in the flunarizine treatment group at
120 mi after treatment (P = 0.04) (Figure 3b).
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Figwe 3 (a) Mean plasma concentrations and (b) mean
tumour-plasma ratios of melphalan with and without flunarizine
(60mg kg-', i.p.) in mice bearing TE-671 MR tumours. Error
bars = s.e.m.
Table 11 Treatment of athymic nude mice beanrng s.c. TE-671 MR xenografts with melphalan ± flunarizine
Experunent Treatmenr T- C (days)b Regression.s Isodose effect ratio
I Melphalan 4.4 1 8 NA
Flunanzine (4 mg kg-') -1.6 0 8
Melphalan + flunarizine 2.5 0 8
2 Melphalan 3.7' 0 7 NA
Flunarizine (4 mg kg-') -0.2 0 '9
Melphalan + flunarizine 2.2 0 9
3 Melphalan 0.4 2 8 NA
Flunarzine (8 mg kg-') 0.3 0 9
Melphalan + flunarizine (8 mg kg-') 2.2 2 9
4 Melphalan 2.6' 0 10 NA
Melphalan + flunarizine (8 mg kg-') 2.8' 0 10
5 Melphalan 4.1' 1 10
Flunarizine(60mgkg-') 1.1 0 10
Melphalan + flunarizine 10.3"j 4 10 2.5
AMelphalan at a dose of 36mgm-2 (0.5 of the 10% lethal dose) in 17% dimethylsulphoxide via i.p. injection:
flunarizine at the indicated dosage in water (pH 4) via i.p. injection 20 min before and subsequently at 8 and 16 h after
treatment with melphalan or 17% dimethylsulphoxide (controls) via i.p. injection. bDifference in days between the
median time for the tumours of treated (T) and control (C) animals to reach a volume offive times greater than the
volume at the time of original treatment. cTumours that decreased in size over two successive measurements/total
tumours. Values not statistically significant compared with controls (P>0.05). dRatio ofgrowth delays ofmelphalan
plus flunarizine melphalan alone; NA, not applicable. 'Values statistically significant as compared with controls
(treated with 17% dimethylsulphoxide) (P<0.01). fStatistically significant as compared with melphalan alone
(P<0.01).
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In this study we found that flunarizine (4 mg kg' i.p.) in-
creased tumour blood flow in TE-671 by 30%, but it had no
effect on tumour regrowth delay induced by melphalan in
either TE-671 or TE-671 MR. In contrast, a flunarizine dose
of 60 mg kg- ' (i.p.) significantly delayed growth in both lines
with a dose-modifying factor near 2 without modification of
blood flow. The enhancement in growth delay was not
associated with a change in plasma pharmacokinetics,
although an increase in the tumour-plasma ratio of mel-
phalan concentration was seen in the resistant line, sugges-
ting decreased drug egress from the tumour. Parallel tumour
regrowth studies with cyclophosphamide in TE-671 showed
no effect of flunarizine in enhancing chemosensitivity. These
results suggest that mechanisms that are operational for
effecting drug egress are different for these two alkylating
agents and that flunarizine works preferentially on drug
egress mechanisms specific for melphalan. It is not possible
to determine from these experiments what the nature of the
egress mechanisms are, but this is an obvious line for further
inquiry. It is possible that the effect is primarily on drug
uptake rather than on egress. In a recent study, the effects of
several calcium channel blockers on melphalan uptake were
evaluated in L5178Y lymphoblasts (Miller et al., 1992).
Verapamil, diltiazem and nitrendipine stimulated melphalan
uptake in this cell line, albeit to varying levels of efficacy.
These same drugs also have some levels of calmodulin inhibi-
tion, but treatment with the calmodulin inhibitor triflu-
operazine actually reduced uptake. Therefore, the ability of
these drugs to affect cellular uptake is probably related to
their calcium channel blocking capability and not their
activity as calmodulin inhibitors.
We have previously published the plasma pharmaco-
kinetics of melphalan in TE-671-bearing mice and showed a
half-life of 29.9 min (Friedman et al., 1986b). These results
are consistent with the published results of Lee and Work-
man (1986), who found a half-life of 26.1 min. The results of
the present study are not inconsistent with these prior
reports, except that peak plasma levels were less than those
we previously observed.
It is generally believed that calcium channel blockers exert
their chemosensitising effect on multidrug resistance (MDR)
by reducing drug egress from cells. The mechanism by which
this ogcurs is not known but is thought to be related to
P-glycoprotein antagonism (Stewart and Evans, 1989). It has
been suggested previously that calcium channel blockers may
reverse non-MDR-associated resistance via their effects on
tumour blood flow (Stewart and Evans, 1989). Our results
clearly demonstrate, however, that modification of drug tox-
icity in this model system by flunarizine is not related to an
increase in blood flow, since the increase in blood flow
observed at the 4mg kg1' flunarizin dose was not associated
with any change in tumour growth delay as compared with
melphalan alone. In contrast, the increased tumour concen-
trations of melphalan associated with the higher lunarzine
dose (60mgkg-') were not associated with blood flow
changes. It is possible that the combination of high-dose
flunarizine and melphalan might have caused changes in
blood flow that were not seen with flunarizine alone; but
given the effects of flunarizine on blood viscosity (see below),
this is an unlikely outcome. These results suggest that the
mechanism of chemosensitisation in this non-MDR-resistant
xenograft model relates to increased retention of melphalan
in tissue that is not regulated by modification of tumour
blood flow. Adams et al. (1989) reported similar results for
the calcium channel blocker nifedipine, although the inves-
tigators did not measure tumour blood flow directly. Instead,
they measured radiobiological hypoxic fraction, which was
not altered at a dose of 10mg kg-' (i.p.), and inferred from
those results that no change in tumour blood flow occurred.
The dose-modifying factor for 60 mg kg-' flunarizine
added to melphalan was approximately 2 for both cell lines.
These results, in combination with the increased tumour-
plasma ratios for melphalan concentration, suggest that drug
egress mechanisms are operational in both lines and that
flunarizne affects these mechanisms to the same extent in
both cell lines.
Flunarizie may also increase the activity of melphalan via
its activity as a calmodulin inhibitor (Lugnier et al., 1984).
Flunarizine is known to be a potent calmodulin inhibitor,
exhibiting activity in the 3-4pM range in vitro. In smooth
muscle preparations, calmodulin-induced contractions were
inhibited at concentrations greater than 101M. Thus, it is
likely that concentrations greater than 1O JM would be
needed to affect calmodulin in vivo. The threshold for cal-
modulin inhibition may explain why the lower concentration
of flunariine was ineffective in modulating melphalan tox-
icity in the TE-671 lines. The 4mgkg-' dose would yield
tissue concentrations in the 5-8 pM range, whereas the
60mgkg-' dose would yield concentrations in the 1OiM
range. There is evidence that calmodulin inhibitors interfere
with DNA repair. For example, decreased repair of
bleomycin-induced DNA damage has been observed in the
presence of the calmodulin inhibitor trifluoperazine (Chafou-
leas et al., 1984). Thus, it is possible that flunarizine was
acting to reduce repair of DNA-protein cross-links induced
by melphalan. However, no enhancement of cyclophos-
phamide toxicity was observed, so the likelihood that this
mechanism was operational is diminished. In addition, the
aforementioned study in L5178Y lymphoblasts showed
decreased drug uptake with calmodulin inhibitors rather than
increased uptake (Miller et al., 1992).
It has been reported that calmodulin inhibitors can also
reduce cellular non-protein thiol content (Shenoy et al.,
1983). In prior work, glutathione depletion by L-buthionine-
sulphoximine created relative increases in growth delay of
37% in TE-671 and 95-113% in TE-671 MR (Rosenberg et
al., 1989). It is believed that part of the mechanism of
resistance in TE-671 MR is due to elevation of glutathione.
The effect of calmodulin inhibitors on thiols, however, occurs
at much higher drug concentrations than those achievable in
vivo. It is not clear, then, whether glutathione depletion is
playing a role in the modification of drug resistance in this
series of experiments. Additional work would be needed to
investigate this further.
The mechanism by which flunarizine modifies tumour
blood flow is speculated to be either vasodilation or a change
in blood viscosity. We recently demonstrated in a rat tumour
model that the increase in tumour blood flow observed with
flunarizine, given at 1 mg kg-' i.v., is accompanied by a
significant increase in perivascular oxygenation within the
tumour (Dewhirst et al., 1992b). Furthermore, the increase in
blood flow and oxygenation is not attributable to changes in
cardiovascular function, tumour feeding vessel diameter,
haemoglobin saturation or microvessel haematocrit. By pro-
cess of elimination, the most likely explanation for the
change in blood flow and oxygenation is a drug-induced
change in blood viscosity. We subsequently showed that
flunarizine reduces blood viscosity in vitro in conditions that
simulate the tumour microenvironment (hypoxia, lactic
acidosis) (Kavanagh et al., 1993). In rat red blood cells, the
optimal drug concentration to achieve this effect is
5-lOmgl-'. In contrast, 50mgl1' yields viscosities not
unlike those from non-drug-containing control conditions.
Parallel studies of cell density and morphology clearly dem-
onstrate that this parabolic dose effect on viscosity is related
to achieving an optimal red cell surface area-volume ratio
that is most conducive to deformability. High doses lead to
spherocytosis (swelling), which reduces deformability. The
results of this current study are in agreement with our prior
work with this drug in that the optimal dose range for
modification of tumour blood flow was 1-5 mg kg-', while
doses of 60 mg kg-' failed to exhibit any rheological change
conducive to modification of tumour blood flow (Kavanagh
et al., 1993). This result is also consistent with prior work by
Wood and Hirst (1989), who demonstrated that optimal
radiosensitisation of a murine tumour model was achieved at
flunarizine doses of 4-5mgkg-' given i.p. Doses in the
range of 50mgkg-' did not result in radiosensitisation.
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It has been reported previously that calcium channel
blockers (verapamil and flunarizine) enhance melphalan
retention and increase its activity in tumours (Robinson et
al.. 1986). These prior results are somewhat difficult to com-
pare with our study because the physiological data were less
complete. Direct measurement of cardiovascular function is
necessary for interpretation of results, particularly with cal-
cium channel blockers that have more direct chronotropic
and inotropic effects than flunarizine, such as verapamIil
(Godfraind et al.. 1986). In the prior studies, measurements
of relative blood flow were made with rubidium-86 uptake.
which measures fraction of cardiac output rather than tissue
perfusion. Therefore, the effects of the calcium channel
blockers on tissue blood flow caused by primary effects on
cardiac function would not necessarily be determined. Cal-
cium channel antagonists such as nimodipine and diltiazem
have been reported to affect Na+. K+-ATPase activity (God-
fraind et al.. 1986). and 'Rb is a potassium analogue. Use of
a potassium analogue to monitor changes in tissue blood
flow. then, may produce artifactually influenced results in the
presence of calcium channel blockers.
Calcium channel blockers and calmodulin inhibitors have
been the subject of extensive investigation as chemosen-
sitisers. particularly in regard to modification of drug resis-
tance. The most active work has been related to modification
of MDR. although some work has also been done in non-
MDR tumours. We chose to study flunarizine in this context
because it is both a calcium channel blocker and a cal-
modulin antagonist (Lugnier et al., 1984). In addition.
flunarizine has been reported to have some antiproliferative
activity on its own, presumably via the calmodulin-
modulated inhibition of DNA synthesis (Sezzi et al., 1984).
We chose flunarizine instead of other available calcium chan-
nel blockers for several reasons. First. other drugs that have
been studied for this type of application, such as verapamil.
do not have calmodulin-modulating activity in a dose range
achievable in iOvo. Secondly. flunarizine, unlike similar drugs.
could be administered over a wide dose range without
appreciable effects on cardiovascular function (Godfraind et
al., 1986). Our physiological results verified the previous
reports. There were no deaths from flunarizine from either
dose. and no increase in frequency of deaths from melphalan
or cyclophosphamide toxicity when flunarizine was added.
Follow-up times post therapy were greater than 30 days in
the TE-671 group, even at the highest melphalan dose
administered (18 mg kg-'). which is 75% of the LD,O. Since
no deaths were observed in this group. the dose-modifying
factor for toxicity must be less than 1.0 0.75 or 1.33. In
addition, plasma pharmacokinetics was not altered by the
mild drop in blood pressure at the 60 mg kg-' dose of
flunarizine. suggesting that renal function was unaltered.
In conclusion, the results of this study demonstrate that
flunarizine, given at a high dose (60 mg kg-'). can create
sensitisation to melphalan cytotoxicity with a dose-modifying
factor ranging from 1.5 to 2.3. The enhancement of drug
effect is not related to changes in tissue blood flow, but is
significantly correlated with decreased drug egress from
tumours. Parallel studies of cyclophosphamiide showed no
enhancement of drug sensitivity. suggesting that the effects of
flunarizine are operational on drug uptake or egress
mechanisms that are specific for melphalan.
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